355 related articles for article (PubMed ID: 31903138)
21. Preclinical efficacy of hK2 targeted [
Timmermand OV; Elgqvist J; Beattie KA; Örbom A; Larsson E; Eriksson SE; Thorek DLJ; Beattie BJ; Tran TA; Ulmert D; Strand SE
Theranostics; 2019; 9(8):2129-2142. PubMed ID: 31149033
[TBL] [Abstract][Full Text] [Related]
22. Noninvasive Imaging of Liposomal Delivery of Superparamagnetic Iron Oxide Nanoparticles to Orthotopic Human Breast Tumor in Mice.
Kato Y; Zhu W; Backer MV; Neoh CC; Hapuarachchige S; Sarkar SK; Backer JM; Artemov D
Pharm Res; 2015 Nov; 32(11):3746-3755. PubMed ID: 26078000
[TBL] [Abstract][Full Text] [Related]
23.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
24. Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles.
Biancacci I; De Lorenzi F; Theek B; Bai X; May JN; Consolino L; Baues M; Moeckel D; Gremse F; von Stillfried S; El Shafei A; Benderski K; Azadkhah Shalmani A; Wang A; Momoh J; Peña Q; Buhl EM; Buyel J; Hennink W; Kiessling F; Metselaar J; Shi Y; Lammers T
Adv Sci (Weinh); 2022 Apr; 9(10):e2103745. PubMed ID: 35072358
[TBL] [Abstract][Full Text] [Related]
25. Design of a novel theranostic nanomedicine: synthesis and physicochemical properties of a biocompatible polyphosphazene-platinum(II) conjugate.
Avaji PG; Park JH; Lee HJ; Jun YJ; Park KS; Lee KE; Choi SJ; Lee HJ; Sohn YS
Int J Nanomedicine; 2016; 11():837-51. PubMed ID: 27042052
[TBL] [Abstract][Full Text] [Related]
26. Impact of surface grafting density of PEG macromolecules on dually fluorescent silica nanoparticles used for the in vivo imaging of subcutaneous tumors.
Adumeau L; Genevois C; Roudier L; Schatz C; Couillaud F; Mornet S
Biochim Biophys Acta Gen Subj; 2017 Jun; 1861(6):1587-1596. PubMed ID: 28179102
[TBL] [Abstract][Full Text] [Related]
27. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
28. N-(2-hydroxypropyl)methacrylamide polymer conjugated pyropheophorbide-a, a promising tumor-targeted theranostic probe for photodynamic therapy and imaging.
Fang J; Šubr V; Islam W; Hackbarth S; Islam R; Etrych T; Ulbrich K; Maeda H
Eur J Pharm Biopharm; 2018 Sep; 130():165-176. PubMed ID: 29885851
[TBL] [Abstract][Full Text] [Related]
29.
Wei X; Liu Z; Zhao Z
Hell J Nucl Med; 2019; 22(1):78-79. PubMed ID: 30968863
[TBL] [Abstract][Full Text] [Related]
30. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
[TBL] [Abstract][Full Text] [Related]
31. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.
Cheal SM; Ruan S; Veach DR; Longo VA; Punzalan BJ; Wu J; Fung EK; Kelly MP; Kirshner JR; Giurleo JT; Ehrlich G; Han AQ; Thurston G; Olson WC; Zanzonico PB; Larson SM; Carrasquillo JA
Mol Pharm; 2018 Jun; 15(6):2133-2141. PubMed ID: 29684277
[TBL] [Abstract][Full Text] [Related]
32. A tumor-targeted polymer theranostics platform for positron emission tomography and fluorescence imaging.
Koziolová E; Goel S; Chytil P; Janoušková O; Barnhart TE; Cai W; Etrych T
Nanoscale; 2017 Aug; 9(30):10906-10918. PubMed ID: 28731080
[TBL] [Abstract][Full Text] [Related]
33. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
Hou L; Shan X; Hao L; Feng Q; Zhang Z
Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
[TBL] [Abstract][Full Text] [Related]
34. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy.
Vosjan MJ; Vercammen J; Kolkman JA; Stigter-van Walsum M; Revets H; van Dongen GA
Mol Cancer Ther; 2012 Apr; 11(4):1017-25. PubMed ID: 22319202
[TBL] [Abstract][Full Text] [Related]
35. Development of [
Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
[TBL] [Abstract][Full Text] [Related]
36. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
[TBL] [Abstract][Full Text] [Related]
37. A Multi-Functional Tumor Theranostic Nanoplatform for MRI Guided Photothermal-Chemotherapy.
Shi J; Wang B; Chen Z; Liu W; Pan J; Hou L; Zhang Z
Pharm Res; 2016 Jun; 33(6):1472-85. PubMed ID: 26984128
[TBL] [Abstract][Full Text] [Related]
38. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
39. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.
Rbah-Vidal L; Vidal A; Billaud EM; Besse S; Ranchon-Cole I; Mishellany F; Perrot Y; Maigne L; Moins N; Guerquin-Kern JL; Degoul F; Chezal JM; Auzeloux P; Miot-Noirault E
Neoplasia; 2017 Jan; 19(1):17-27. PubMed ID: 27987437
[TBL] [Abstract][Full Text] [Related]
40. In vivo biokinetic and metabolic characterization of the ⁶⁸Ga-labelled α5β1-selective peptidomimetic FR366.
D'Alessandria C; Pohle K; Rechenmacher F; Neubauer S; Notni J; Wester HJ; Schwaiger M; Kessler H; Beer AJ
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):953-963. PubMed ID: 26497698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
